Physicians' Academy for Cardiovascular Education

A Randomized Phase 3 Trial Evaluating Alirocumab Every Four Weeks Dosing as Add-on to Statin or as Monotherapy: ODYSSEY CHOICE I

June 19, 2015

Presentation prepared and held by Dr. Eli Roth (Cincinatti, Ohio, USA) in Clinical Breakthroughs session: Modifying LDL cholesterol to prevent CV events, Tuesday, May 26, 2015 during ISA2015 (Amsterdam, The Netherlands).

To view slides, click on images

Roth_CHOICE_I_ISA2015_Oral__R727_CL_1308__23May2015_FINAL.pdf (0,7MB)Roth_CHOICE_I_ISA2015_Oral__R727_CL_1308__23May2015_FINAL.pdf (0,7MB)